Notice2022-02469
National Institute on Drug Abuse; Notice of Closed Meetings
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 7, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 25 (Monday, February 7, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 25 (Monday, February 7, 2022)]
[Notices]
[Pages 6878-6879]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-02469]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications and the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIH Support for Conferences and Scientific Meetings.
Date: March 4, 2022.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827-5819, <a href="/cdn-cgi/l/email-protection#ee8983dfdadb8fae808786c0898198"><span class="__cf_email__" data-cfemail="26414b1712134766484f4e08414950">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Fentanyl and its Analogs: Effects and Consequences
for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial
Optional).
Date: March 9, 2022.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, 301-443-
4577, <a href="/cdn-cgi/l/email-protection#5a343b233b282a681a39292874343332743d352c"><span class="__cf_email__" data-cfemail="7719160e160507453714040559191e1f59101801">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; SEP for Centers Review.
Date: March 9, 2022.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sheila Pirooznia, Ph.D., Scientific Review
Officer, Scientific Review Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892,
(301) 496-9350, <a href="/cdn-cgi/l/email-protection#fd8e959894919cd38d948f92928793949cbd939495d39a928b"><span class="__cf_email__" data-cfemail="b9cad1dcd0d5d897c9d0cbd6d6c3d7d0d8f9d7d0d197ded6cf">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; for Avenir Review.
Date: March 21, 2022.
Time: 3:00 p.m. to 4:00 p.m.
[[Page 6879]]
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827-4471, <a href="/cdn-cgi/l/email-protection#047665696560656a6d764469656d682a6a6d6c2a636b72"><span class="__cf_email__" data-cfemail="cbb9aaa6aaafaaa5a2b98ba6aaa2a7e5a5a2a3e5aca4bd">[email protected]</span></a>.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: February 1, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-02469 Filed 2-4-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 7, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.